Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell VaccinationMassimo Di Nicola, Andrea Anichini, Alessandro M. Gianni et al.|Clinical Cancer Research|2004Cited by 83
miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediatorsElisabetta Vergani, Viviana Vallacchi, Matteo Dugo et al.|Cell Communication and Signaling|2020Cited by 36
Immunization of Patients with Malignant Melanoma with Autologous CD34 <sup>+</sup> Cell-Derived Dendritic Cells Transduced <i>Ex Vivo</i> with a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I TrialMassimo Di Nicola, Alessandro M. Gianni, Carmelo Carlo‐Stella et al.|Human Gene Therapy|2003Cited by 21
Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional ProfilesElisabetta Vergani, Monica Rodolfo, Adele Busico et al.|Journal of Investigative Dermatology|2022Cited by 14
Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with <i>BRAF</i> Mutated MelanomaLorenza Di Guardo, Michele Del Vecchio, Giovanni Randon et al.|The Oncologist|2021Cited by 10